TTNP (Titan Pharmaceuticals) Cyclically Adjusted PS Ratio: (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TTNP Titan Pharmaceuticals Inc TTNP
9 GF Score
Price $4.61
View Full Analysis

What is Titan Pharmaceuticals Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Titan Pharmaceuticals  (NAS:TTNP) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Titan Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms


Titan Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Titan Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Titan Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Titan Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.02 0.02 0.00 0.00

Titan Pharmaceuticals Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TTNP vs TCRT, SXTP, KTTA: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Titan Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Titan Pharmaceuticals Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Titan Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Titan Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


TTNP
9GF Score
Titan Pharmaceuticals Inc TTNP
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Titan Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Titan Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2025 is calculated as:

For example, Titan Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2025 (Change)*Current CPI (Jun. 2025)
=0/322.5610*322.5610
=0.000

Current CPI (Jun. 2025) = 322.5610.

Titan Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201509 0.000 237.945 0.000
201512 0.000 236.525 0.000
201603 0.000 238.132 0.000
201606 2,500.667 241.018 3,346.711
201609 4.333 241.428 5.789
201612 5.833 241.432 7.793
201703 6.667 243.801 8.821
201706 12.833 244.955 16.899
201709 6.667 246.819 8.713
201712 9.667 246.524 12.649
201803 177.333 249.554 229.212
201806 444.667 251.989 569.200
201809 275.000 252.439 351.389
201812 24.091 251.233 30.931
201903 28.636 254.202 36.337
201906 13.217 256.143 16.644
201909 7.308 256.759 9.181
201912 -8.427 256.974 -10.578
202003 0.000 258.115 0.000
202006 0.285 257.797 0.357
202009 0.000 260.280 0.000
202012 1.384 260.474 1.714
202103 0.244 264.877 0.297
202106 0.187 271.696 0.222
202109 0.081 274.310 0.095
202112 0.008 278.802 0.009
202203 0.006 287.504 0.007
202206 0.004 296.311 0.004
202209 0.005 296.808 0.005
202212 0.070 296.797 0.076
202303 0.000 301.836 0.000
202306 0.001 305.109 0.001
202309 0.000 307.789 0.000
202312 0.000 306.746 0.000
202403 0.000 312.332 0.000
202406 0.000 314.175 0.000
202409 0.000 315.301 0.000
202412 0.000 315.605 0.000
202503 0.000 319.799 0.000
202506 0.000 322.561 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Titan Pharmaceuticals Business Description

Address 400 Oyster Point Boulevard, Suite 505, South San Francisco, CA, USA, 94080
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
9GF Score

Get the complete analysis for TTNP

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.61
Price